New Data on the Neuromonics Tinnitus Treatment Presented Today at AudiologyNOW! Conference
BETHLEHEM, Pa. & DALLAS--(BUSINESS WIRE)--Neuromonics, Inc. today announced new, interim results of its Customized Acoustic Stimulation for Long-Term Medical Benefit (CALM) study, at the AudiologyNOW! 2009 meeting in Dallas. The data show that treatment with Neuromonics reduces psycho-social consequences and distress from tinnitus. Treatment response occurs within two months and improves over time. Neuromonics is an FDA-cleared treatment that addresses the neurological processes of tinnitus, specifically its audiological, attention-based and emotional aspects.